The mutated version of the virus exhibited resistance to the antiviral drug remdesivir.
on Medrxiv, researchers found that a woman in her 70s who had been treated with the drug had failed to completely clear her Covid-19 infection for several months.
A genetic examination of the virus showed that it had mutated during treatment in a manner that reduced the effectiveness of the antiviral drug, manufactured by Gilead. Professor Akiko Iwasaki, one of the study’s authors, remdesivir initially brought the patient’s viral load down but it rose again during the course of the remdesivir treatment.
The persistent infection was eventually successfully treated using monoclonal antibodies, according to the study. The woman who exhibited the mutation was immunocompromised as she had previously been treated for non-Hodgkin’s lymphoma.“This case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection,” the study’s authors wrote in the preprint.0.003%. That’s the percentage of cases from 4.1 million genome sequences obtained from patients which showed the mutation, Prof.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Sleep apnea severity linked to COVID-19 outcomesThe following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.
Les mer »
Sleep apnea severity linked to COVID-19 outcomesThe following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.
Les mer »